Vivani Medical, Inc. (NASDAQ:VANI – Get Rating) was down 2.5% on Tuesday . The stock traded as low as $0.86 and last traded at $0.91. Approximately 119,948 shares changed hands during mid-day trading, an increase of 4% from the average daily volume of 115,268 shares. The stock had previously closed at $0.93.
Analyst Upgrades and Downgrades
Separately, ThinkEquity started coverage on Vivani Medical in a report on Monday, December 5th. They issued a "buy" rating and a $7.00 price target for the company.
Get
Vivani Medical alerts:
Vivani Medical Stock Down 2.5 %
The firm has a fifty day moving average price of $1.52.
Institutional Investors Weigh In On Vivani Medical
A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp acquired a new stake in shares of Vivani Medical during the third quarter worth about $63,000. Vanguard Group Inc. acquired a new stake in shares of Vivani Medical during the third quarter worth about $682,000. Prelude Capital Management LLC acquired a new stake in shares of Vivani Medical during the third quarter worth about $25,000. BlackRock Inc. acquired a new stake in shares of Vivani Medical during the third quarter worth about $734,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Vivani Medical during the third quarter worth about $822,000.
Vivani Medical Company Profile
(Get Rating)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Featured Stories
- Get a free copy of the StockNews.com research report on Vivani Medical (VANI)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Vivani Medical, Inc. (NASDAQ:VANI – Get Rating) was down 2.5% on Tuesday . The stock traded as low as $0.86 and last traded at $0.91. Approximately 119,948 shares changed hands during mid-day trading, an increase of 4% from the average daily volume of 115,268 shares. The stock had previously closed at $0.93.
周二,Vivani Medical, Inc.(纳斯达克股票代码:VANI — 获取评级)下跌2.5%。该股的交易价格低至0.86美元,最后一次交易价格为0.91美元。在午盘交易中,约有119,948股易手,较平均每日交易量115,268股增长了4%。该股此前收于0.93美元。
Analyst Upgrades and Downgrades
Separately, ThinkEquity started coverage on Vivani Medical in a report on Monday, December 5th. They issued a "buy" rating and a $7.00 price target for the company.
另外,ThinkeQuity在12月5日星期一的一份报告中开始报道Vivani Medical。他们为该公司发布了 “买入” 评级和7.00美元的目标价。
Get
Vivani Medical
alerts:
Vivani Medical Stock Down 2.5 %
Vivani Medical 股票下跌 2.5 %
The firm has a fifty day moving average price of $1.52.
Institutional Investors Weigh In On Vivani Medical
A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp acquired a new stake in shares of Vivani Medical during the third quarter worth about $63,000. Vanguard Group Inc. acquired a new stake in shares of Vivani Medical during the third quarter worth about $682,000. Prelude Capital Management LLC acquired a new stake in shares of Vivani Medical during the third quarter worth about $25,000. BlackRock Inc. acquired a new stake in shares of Vivani Medical during the third quarter worth about $734,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Vivani Medical during the third quarter worth about $822,000.
一些机构投资者和对冲基金最近修改了对该公司的持股。State Street Corp在第三季度收购了Vivani Medical的新股份,价值约63,000美元。Vanguard Group Inc.在第三季度收购了Vivani Medical的新股份,价值约68.2万美元。Prelude Capital Management LLC在第三季度收购了Vivani Medical的新股份,价值约25,000美元。贝莱德公司在第三季度收购了Vivani Medical的新股份,价值约73.4万美元。最后,联邦股票服务有限责任公司在第三季度收购了Vivani Medical的新股份,价值约82.2万美元。
Vivani Medical Company Profile
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Vivani Medical, Inc是一家临床阶段的公司,开发了各种植入物,用于治疗医疗需求未得到满足的慢性病。它致力于开发微型药物植入物产品组合,以提供最小的药物特征波动;以及用于为盲人提供有用的人工视觉的植入式视觉假体设备组合。
Featured Stories
- Get a free copy of the StockNews.com research report on Vivani Medical (VANI)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
- 免费获取 StockNews.com 关于 Vivani Medical (VANI) 的研究报告
- 3 只工业股将帮助您建立 2023 年关注名单
- 机构选择 CarMax 而不是 Carvana,你应该吗?
- 交易热图:如何了解市场深度隐藏了什么
- 美光科技预计芯片将在2023年底之前复苏
- 新年值得关注的三只医疗保健细价股
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Vivani Medical Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Vivani Medical及相关公司的最新新闻和分析师评级的简明每日摘要。